Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
about
The impact of the Medicare Part D prescription benefit on generic drug useAssociation between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic reviewPhysicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug ApprovalA blueprint for pharmacy benefit managers to increase valuePotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsComparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy.A drug utilization study to provide background data for bringing amendments in the drug dispensing policy of a pediatric referral center.Consumers' views on generic medicines: a review of the literature.Drug utilization study in medical emergency unit of a tertiary care hospital in north India.The Portuguese generic medicines market: a policy analysis.Drug utilisation study in a tertiary care center: recommendations for improving hospital drug dispensing policies.Impact of generic substitution decision support on electronic prescribing behaviorSpecial challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway.Association of income and prescription drug coverage with generic medication use among older adults with hypertensionPatients' beliefs about generic medicines in Malaysia.Beliefs about generic drugs among elderly adults in hospital-based primary care practicesCost savings associated with filling a 3-month supply of prescription medicines.Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006-2010).Biosimilars: the debate continues.Cyclosporine: A Commentary on Brand versus Generic Formulation ExchangeVariability in drug formularies and implications in decision support.Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions.Community pharmacists' attitudes toward the quality and price of locally manufactured generic medicines in Kabul, Afghanistan.What's in a name? Use of brand versus generic drug names in United States outpatient practice.Efficacy and Safety of Dorocontin(®) versus Sustac(®) in the Treatment of Stable Angina Pectoris: A Randomized, Double-Blind Comparative Trial.Generic medicines and generic substitution: contrasting perspectives of stakeholders in IrelandTeaching WiselyDo newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.Does educational intervention improve doctors' knowledge and perceptions of generic medicines and their generic prescribing rate? A study from Malaysia.Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review.Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication useDeterminants of pharmaceutical expenditures of urban households: A time series study in Kermanshah province (Iran)Perception of generic prescription drugs and utilization of generic drug discount programs.Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.Perception and attitude of physicians toward local generic medicines in Saudi Arabia: A questionnaire-based study.What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.How can bedside rationing be justified despite coexisting inefficiency? The need for 'benchmarks of efficiency'.Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study
P2860
Q24652400-C17BFB6A-5D6B-48AB-9956-00C20730C2F5Q28541457-E1CEF507-7A13-4BB3-835C-9EB060F90FCFQ28552883-6DDA4B96-34EC-466B-8E12-8390B757CDC5Q28766235-B4210702-B73C-487A-9F5E-B1818F4B3F25Q29393270-1CF7715A-FE46-4E42-9780-60884480FE03Q33404843-5EDAF4C5-EFC1-490D-8BAA-763AC2A1E06DQ33519604-40F2DF6E-8027-401F-B18C-445B96F52356Q33538811-E9924BD9-F213-481A-93E8-E50A0756A36EQ33634851-48FB8E5D-E3A2-47FA-A837-729B37D127B8Q34072045-D873334C-9A14-4080-A2BB-088A1B2AE372Q34228925-5A3A5D0E-A8D3-48DF-851E-899C98B282F7Q34399756-F7AABCD7-E4E4-4C18-8C5E-AA4ACCBB959DQ34494595-0CF16E66-C722-494C-92EE-D740ABA9CBFAQ34552299-87B74916-81A1-4500-A853-97EF3A383A16Q34808424-02A147CF-D797-4027-B558-3D6C685E0CE0Q34809382-F6419C59-3731-45B9-8257-0272CA8D5201Q35012332-85C1F3B6-DCBB-45F0-812C-602C4364577CQ35102825-6104FA51-C626-47E3-A46F-7A3B0F0B2F29Q35432608-9946C7D4-800F-4286-A913-B838F2CF52E3Q35607575-95A930B9-A42F-45DD-9CCB-46453F9B0B47Q35625221-18390448-7E5E-430F-A5FF-33E79BCB1A6BQ35641265-929754E4-67AD-402C-91FE-934C93D9C720Q35741403-E70722CB-0066-442E-8AA9-3F6518F4E425Q35753043-F104CC2E-E67E-41D6-AF7B-8AB66DE1C2BAQ35763860-784A340C-A949-442B-B709-648EC04F8121Q35869235-F541F3E2-6801-40E9-8024-66E9BD298F41Q35949491-6D26EA08-6839-41C0-8AB0-5059E601ECA4Q35990559-30B75237-FB7E-4DAD-858D-64DA75F2276FQ36165954-8D668FED-1517-48EB-B842-74CD3C597DE5Q36235657-307B25E9-710E-4222-BADF-86A09A57C7F0Q36416773-7A650720-CBFF-4C0D-BA36-ADA9784CAB2AQ36429238-C1F463C5-5528-4D8C-93AE-A9EE47FDE91AQ36466028-04FBE8FB-C4CA-4803-8D8E-B594A2384F7FQ36681017-C99F5D28-D49E-4BBD-A2BF-0FCD4A1701E6Q36806877-A15992C9-BCF7-41C3-8AC2-6E6ECE7D749EQ36841041-FE3C8BB5-7008-4197-AB1A-8CCF3C6EAF86Q36848547-E8B98B9D-DF64-4C80-BF81-91A9FBF018BBQ36916999-C02F02D1-D3AE-4EF1-B02A-2179E5A75B7DQ37196480-F040618A-13CF-43EB-9067-4B11F2DB3C2DQ37271349-EDD5A229-E5DF-45BC-882C-FAAC26BA689D
P2860
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Potential savings from substit ...... iture panel survey, 1997-2000.
@en
Potential savings from substit ...... iture panel survey, 1997-2000.
@nl
type
label
Potential savings from substit ...... iture panel survey, 1997-2000.
@en
Potential savings from substit ...... iture panel survey, 1997-2000.
@nl
prefLabel
Potential savings from substit ...... iture panel survey, 1997-2000.
@en
Potential savings from substit ...... iture panel survey, 1997-2000.
@nl
P2093
P1476
Potential savings from substit ...... diture panel survey, 1997-2000
@en
P2093
Andrew C Seger
Eric P Gerstenberger
Kathryn A Phillips
P304
P356
10.7326/0003-4819-142-11-200506070-00006
P407
P577
2005-06-01T00:00:00Z